Tuesday, 07 Apr 2020

You are here

RheumNow Podcast – Better Ways to Treat Gout (11.8.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

  1. Study of ANA+ people without lupus or CTD shows that fatigue does not increase odds of having lupus or CTD. 1/3 of ANA referrals had FM and fatigue was correlated with widespread pain. https://t.co/g8NqHzLngw
  2. Methotrexate - an old drug with new tricks! new publication reviews the use of MTX in the management of chronic viral arthritis, including chikungunya and other old world alphaviruses, Parvovirus B19, hepatitis B/C virus, and human immunodeficiency virus https://t.co/HY2a5c1Ia9
  3. Retrospective study from Spanish SLE register RELESSER: in 3539 SLE patients, the risk of cancer was elevated (SIR=1.37; CI 95%: 1.15‐1.59), higher in women (SIR=2.38). SLICC Dz activity and ACE inhibitor use was assoc w/ non-Hormone sensitive CA https://t.co/epJsTdblpX
  4. Cancer Risk with psoriasis? Metanalysis of 58 studies shows that PSO is associated with an 18-22% increased risk of all cancers, highest w/ severe PSO. Increased risk of colon, laryngeal, liver, lymphoma/NHL, esophageal, oral cavity & pancreatic CA https://t.co/HYOej7mrbQ
  5. CONTACT trial compared colchicine 0.5 mg tid vs naproxen 250 mg tid in treating 399 patients with acute #gout. Both drugs equally controlled patient pain, but had more diarrhea (46% vs 20%) and headache (20.5% vs 10.7%) in first 7 days. http://bit.ly/2WUWOJ1 
  6. Analysis of 92 #Gout pts treated with pegloticase compared pre-Rx prophylaxis with IV hydrocortisone or methylprednisolone (MP), finds that IV MP had more PEG infusions (8.5 vs 4.9) & fewer infusion reactions (8% vs 42%) compared with IV hydrocortisone https://t.co/K0jr5qdFbD
  7. T2T Lowers Mortality in Gout     
  8. New EMA Warnings for Tofacitinib in Patients at Risk for Clots   
  9. EXCEED Study: Cosentyx Equals Humira in Psoriatic Arthritis   
  10. Rinvoq (upadacitinib) Effective in Psoriatic Arthritis 
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

COVID-19 Susceptibility: Why Do Some Become So Ill?

The differential susceptibility to COVID-19 infection is attributable to socioeconomic factors and genetic differences, that together with environmental factors, human-virus interactions, gender, perhaps blood type, and age-related senescence determine the immune response and the likelihood of developing disease.

NICE Guidelines on Managing Rheumatologic Conditions During COVID-19 Pandemic

On April 3rd, the National Institute for Health and Care Excellence (NICE) in the UK, published a rapid guideline for managing children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection.

RheumNow Podcast – Pandemic Numbers (4.3.20)

Dr. Jack Cush reviews the news on COVID-19 and FDA actions this past week. Be sure to check out:

CDC: Impact of Underlying Health Conditions Among COVID-19 Patients

The March 31 release of the Morbidity and Mortality Weekly Report (MMWR) reviews the impact of several key comorbidities, most commonly diabetes mellitus, chronic lung disease, and cardiovascular disease, as cofactors leading to worse outcomes with COVID-19 infections.  Below are experts from that report.

TeleRheumatology - a TED Talk by Alvin Wells, MD

RheumNow Live 2020 featured a series of shorter STEP (TED-like) talks. This one features Dr. Alvin Wells discussing the opportunities and new paradigms encumbent with telemedicine in rheumatology.